Archive — US — techcrunch
University spin-out Afynia secures $5M seed to commercialize its microRNA paneltest for endometriosis
Afynia Laboratories, a Canadian biotech spin-out from McMaster University, has secured $5 million in seed funding to develop EndomiR, a blood test for diagnosing endometriosis. This complex condition, affecting nearly 200 million globally, often takes years to diagnose, delaying treatment. Afynia aims to expedite diagnosis via a microRNA panel test, enhancing patient outcomes and trust in non-invasive diagnostic measures.
Key points
- Afynia Laboratories raised $5 million in seed funding.
- The focus is on commercializing EndomiR, a blood test for endometriosis.
- Endometriosis affects approximately 200 million people worldwide, making diagnosis challenging.
- The test uses a microRNA panel, allowing for improved detection from various disease types and stages.
- Dr. Lauren Foster emphasizes the need for a multi-biomarker approach for consistency and reliability.
- Afynia plans to launch the test in Canada and then in the U.S. by early next year.
Why it matters
- Endometriosis has historically been under-researched, creating significant delays in diagnosis.
- In recent years, advancements in biotechnology have led to a rise in precision medicine, including non-invasive diagnostics.
- The trend towards telehealth and remote testing aligns with patient demands for less invasive diagnostic methods.
- In the context of 2025 IT trends, the use of AI and data analytics in healthcare diagnostics is becoming increasingly prominent.
Afynia's innovative approach with the EndomiR test marks a significant step towards faster diagnosis of endometriosis, potentially transforming patient care and addressing long-standing challenges faced by millions.